It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...

WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved ...

Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . Seborrheic dermatitis is often treated with topical antifungals or corticosteroids, which can be cumbersome on ...

Please provide your email address to receive an email when new articles are posted on . The FDA will review a new drug application for roflumilast foam 0.3% to treat seborrheic dermatitis in patients ...

If the skin under your facial hair is often red, irritated, itchy or flaky, the culprit could be a condition called seborrheic dermatitis. This is the same condition that causes dandruff on the scalp, ...

Dear Dr. Gott: My husband has been diagnosed with seborrheic dermatitis. Medication has been ineffective. We have been using Neosporin and antiseptic powder on the open areas and aloe vera on his ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...

TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...